JAC Advance Access originally published online on April 14, 2003
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Journal of Antimicrobial Chemotherapy (2003) 51, 1253-1260
© 2003 The British Society for Antimicrobial Chemotherapy
Efficacy of ertapenem in the treatment of serious infections caused by Enterobacteriaceae: analysis of pooled clinical trial data
Merck Research Laboratories, West Point, PA 19486-0004, USA
Received 3 December 2002; returned 1 January 2003; revised 13 January 2003; accepted 3 March 2003
Objective: The efficacy of ertapenem, 1 g once a day, for treatment of adults with serious infections caused by Enterobacteriaceae was compared with ceftriaxone 1 g once a day [complicated urinary tract infection (CUTI) and community-acquired pneumonia (CAP)] or piperacillin–tazobactam, 3.375 g every 6 h (complicated intra-abdominal, complicated skin/skin structure and acute pelvic infections).
Patients and methods: This combined analysis included the subgroup of all 1167 treated patients infected with Enterobacteriaceae from seven randomized double-blind studies.
Results: Escherichia coli was the most common pathogen, accounting for 65.3% of all Enterobacteriaceae. Among evaluable patients with deep tissue (intra-abdominal, skin and pelvic) infections, the combined clinical cure rates were 84.8% (223 of 263) for ertapenem and 82.9% (194 of 234) for piperacillin–tazobactam [95% confidence interval (CI) for the difference, adjusting for infection, –4.9% to 8.9%]. Cure rates by infection for ertapenem and piperacillin–tazobactam, respectively, were: intra-abdominal, 85.1% (143 of 168) and 79.9% (119 of 149); pelvic, 86.8% (46 of 53) and 94% (47 of 50); skin/skin structure, 81% (34 of 42) and 80% (28 of 35). Among patients with CUTI, microbiological cure rates were 90.5% (220 of 243) for ertapenem and 92% (196 of 213) for ceftriaxone (95% CI for the difference, –7.1% to 4.1%). In patients with CAP, clinical cure rates were 95% (19 of 20) for ertapenem and 88.9% (16 of 18) for ceftriaxone.
Conclusion: Ertapenem therapy was as effective as either piperacillin–tazobactam or ceftriaxone for serious infections caused by Enterobacteriaceae.
Keywords: ertapenem, Enterobacteriaceae, Escherichia coli, intra-abdominal infection, skin infection
* Correspondence address. Merck & Co., Inc., 10 Sentry Parkway, BL3-4, Blue Bell, PA 19422, USA. Tel: +1-484-344-2481; Fax: +1-484-344-3404; E-mail: gail_woods{at}merck.com
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  H. Xiao, J. Siddiqui, and D. G. Remick Mechanisms of Mortality in Early and Late Sepsis Infect. Immun., September 1, 2006; 74(9): 5227 - 5235. [Abstract] [Full Text] [PDF]
|
|